Patents Assigned to Governors of the University of Alberta
  • Patent number: 10408844
    Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a subject. The methods and compositions involve measurement of at least one of proteins: IL-16, IL-7, VEGF, CXCL9, CX3CL1, CCL24, CCL19, and CCL11 in a body fluid sample of a subject suspected of having CFS/ME. Levels of one or more of the aforementioned proteins can be used to facilitate a diagnosis of a CFS/ME and/or confirm a diagnosis of CFS/ME. The methods and compositions of the present disclosure also find use in screening subjects for clinical trials and facilitating treatment decisions for a subject.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: September 10, 2019
    Assignee: The Governors of the University of Alberta
    Inventors: Abdolamir Landi, David Broadhurst, D. Lorne J. Tyrrell, Michael Houghton
  • Patent number: 10405834
    Abstract: An anatomical structure is segmented from images generated in an anatomical scan. A user input device is configured for manually identifying two or more seed points on a plurality of the images. An image processor is configured to identify an optimal path through seed points on the plurality of images with a graph search. The optimal path between corresponding seed points on different images defines a boundary contour, and the anatomical structure includes two or more boundary contour. The image processor is further configured to interpolate the boundary contours over a three-dimensional volume using cardinal splines.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: September 10, 2019
    Assignee: The Governors of the University of Alberta
    Inventors: Jacob Lester Jaremko, Abhilash Hareendranathan, Myles Mabee, Richard Thompson, Pierre Boulanger, Kumaradevan Punithakumar
  • Publication number: 20190271701
    Abstract: Methods for the diagnosis of CRC, colorectal polyps in general and adenomatous polyps in particular by measurement of metabolites in urine are described. In some embodiments, certain metabolites are identified as being elevated or reduced in concentration or quantity in subjects with CRC and/or colorectal polyps as compared with subjects without CRC or colorectal polyps. The measurement of these metabolites in urine can indicate the presence of CRC or colorectal polyps in general or adanomatous polyps in particular in a subject.
    Type: Application
    Filed: March 6, 2019
    Publication date: September 5, 2019
    Applicant: The Governors Of The University of Alberta
    Inventors: Richard Neil Fedorak, Haili Wang
  • Publication number: 20190270782
    Abstract: Disclosed are methods and pharmaceutical compositions for treating and inhibiting conical vascularization including conical vascularization associated with viral infection, chemical injury, autoimmune conditions, and post-corneal transplantation or in subjects having a PAX6 mutation associated with conical vascularization. The methods and pharmaceutical compositions are utilized in administering treatment that results in increased concentration of FOXC1 in a subject's cornea in order to treat or inhibit corneal vascularization.
    Type: Application
    Filed: February 18, 2019
    Publication date: September 5, 2019
    Applicants: Northwestern University, The Governors of the University of Alberta
    Inventors: Tsutomu Kume, Ordan Lehmann
  • Patent number: 10392426
    Abstract: The invention, in some aspects relates to light-activated ion channel polypeptides and encoding nucleic acids and also relates in part to compositions comprising light-activated ion channel polypeptides and methods using light-activated ion channel polypeptides to alter cell activity and function.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 27, 2019
    Assignees: Massachusetts Institute of Technology, The Governors of the University of Alberta, President and Fellows of Harvard College
    Inventors: Nathan Klapoetke, Edward Boyden, Yongku Cho, Brian Y. Chow, Gane K. S. Wong, Adam E. Cohen, Daniel R. Hochbaum
  • Publication number: 20190233735
    Abstract: The methods described herein provide an efficient way to remove and isolate short chain fatty acids from hydrocarbons that are produced upon the heating of a fatty acid resource. The short chain fatty acids can be continuously isolated and fed into the pyrolysis reactor, which in turn increases the overall efficiency of the production of the hydrocarbons. Alternatively, the short chain fatty acids can be isolated and used in other applications.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 1, 2019
    Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventor: David BRESSLER
  • Patent number: 10364208
    Abstract: Described herein are methods of oxidative coupling of aryl boron reagents with sp3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: July 30, 2019
    Assignee: The Governors of the University of Alberta
    Inventors: Rylan Lundgren, Patrick Moon
  • Patent number: 10364440
    Abstract: The present invention is directed to transfection complexes of rosette nanotubes and one or more nucleic acids.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: July 30, 2019
    Assignees: Brown University, Rhode Island Hospital, The Governors of the University of Alberta, National Research Council of Canada
    Inventors: Thomas J. Webster, Qian Chen, Yupeng Chen, Hicham Fenniri, Usha Devi Hemraz
  • Patent number: 10350246
    Abstract: The present application discloses the use of light-gated cation-selective channelrhodopsins (Ch Rs) for the optogenetic control of the secretion of a polypeptide of interest in adipocytes. Engineered adipocytes comprising a channelrhodopsin (ChR) polypeptide, and/or a nucleic acid encoding same, and a secretory polypeptide precursor comprising a bioactive polypeptide and a signal peptide suitable for secretion of the bioactive polypeptide by the engineered adipocytes, and/or a nucleic acid encoding same, are disclosed. The use of such engineered adipocytes for the management or treatment of diseases/conditions in which the secretion of a polypeptide of interest is beneficial, such as the secretion of insulin in diabetic patients, is also disclosed.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: July 16, 2019
    Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventor: Peter Edward Light
  • Patent number: 10344300
    Abstract: The present invention is directed to transfection complexes of rosette nanotubes and one or more nucleic acids.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: July 9, 2019
    Assignees: Brown University, Rhode Island Hospital, The Governors of the University of Alberta, National Research Council of Canada
    Inventors: Yunpeng Chen, Qian Chen, Thomas J. Webster, Hicham Fenniri, Usha Devi Hemraz
  • Patent number: 10342838
    Abstract: The present disclosure embraces methodology and compositions for preparing pea seed coat fractions conferring improved health and/or other beneficial effects, and such fractions may be used in a human and/or animal diet.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: July 9, 2019
    Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Jocelyn Ozga, Catherine Chan, Alena Jin, Han Yang, Seyede Zohre Hashemi, Kaiyuan Yang
  • Patent number: 10300131
    Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: May 28, 2019
    Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Michael Houghton, John L. Law, Michael Logan, Darren Hockman, Abdolamir Landi
  • Patent number: 10266603
    Abstract: The invention includes method, pharmaceutical compositions and uses thereof for treating patients with Papillary Thyroid Carcinoma (PTC) using a Platelet Derived Growth Factor Receptor Alpha (PDGFRA) inhibitor. The PDGFRA inhibitor is preferably an antibody specific to PDGFRA and causes an increase in the sensitivity level of PTC cells to radioiodine treatment. Moreover, the antibody can be used in combination with other PDGFRA inhibitors such as tyrosine kinase inhibitors and RNA interference molecules.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: April 23, 2019
    Assignee: The Governors of the University of Alberta
    Inventors: Todd McMullen, Ana Lopez-Campistrous, David Williams
  • Patent number: 10267800
    Abstract: Methods for the diagnosis of CRC, colorectal polyps in general and adenomatous polyps in particular by measurement of metabolites in urine are described. In some embodiments, certain metabolites are identified as being elevated or reduced in concentration or quantity in subjects with CRC and/or colorectal polyps as compared with subjects without CRC or colorectal polyps. The measurement of these metabolites in urine can indicate the presence of CRC or colorectal polyps in general or adanomatous polyps in particular in a subject.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: April 23, 2019
    Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Richard Neil Fedorak, Sr., Haili Wang
  • Patent number: 10258680
    Abstract: The present application provides a vaccine composition comprising: bacteria engineered to express at least one N-glycan of Campylobacter, such as C. jejuni for example, or an N-glycan derivative thereof on its cell surface; and one or more of a physiologically acceptable diluent, excipient, adjuvant or carrier. The bacteria is Escherichia coli, Salmonella or any suitable bacteria that offers sufficient expression and improved immunogenic response. The vaccine composition can be formulated for administration to animals, such as poultry, including chickens.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: April 16, 2019
    Assignee: The Governors of the University of Alberta
    Inventors: Christine Szymanski, Harald Nothaft
  • Patent number: 10253268
    Abstract: Described herein are methods for producing branched alkanes and branched alkenes from the pyrolysis of radical precursors.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 9, 2019
    Assignee: The Governors of the University of Alberta
    Inventor: David Bressler
  • Publication number: 20190083027
    Abstract: A device for measuring spinal stiffness comprises a frame-work supporting a roller that is rolled over the surface of the back. The device creates and records a trajectory across a subject, using a control board and the roller, and moves the roller along the trajectory while applying a force to the subject using the roller and records displacement of the object in the direction of the force. A stiffness map is created using displacement as a function of force. Motors may be used to move the roller through three axes.
    Type: Application
    Filed: March 29, 2017
    Publication date: March 21, 2019
    Applicant: The Governors of the University of Alberta
    Inventor: Greg Kawchuk
  • Publication number: 20190079082
    Abstract: A method of determining risk of stress in a subject involves determining in a biological sample, the level of one or more forms of calcium binding protein spermatid specific 1 protein, wherein the one or more forms comprise one or more of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms; comparing the level of the one or more forms in the sample with the level of the one or more forms in a normal control; determining whether the subject has risk of stress in accordance with the result; wherein a difference in the level of the one or more forms relative to the level of the normal control, is indicative of stress or responsiveness to stressful stimuli; and treating the subject with a stress management program that involves using one or more forms of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms as therapeutic targets.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 14, 2019
    Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Dean BEFUS, Thomas RITZ, Chris ST. LAURENT, Katherine ST. LAURENT
  • Patent number: 10207006
    Abstract: There is provided a method of detecting in a sample the presence of an anti-M and/or anti-A and/or anti-C/Y antibody, the method comprising contacting the sample with a diagnostic conjugate provided according to the invention, comprising an oligosaccharide which comprises at least two units of 4,6-dideoxy-4-acylamido-?-pyranose and comprising at least one -(1-3)- link between adjacent 4,6-dideoxy-4-acylamido-?-pyranose units, in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from —CH2OH, —H or an alkyl group having at least one C atom, the oligosaccharide being covalently linked to a non-saccharide molecule or to a surface.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: February 19, 2019
    Assignees: THE SECRETARY OF STATE FOR ENVIRONMENT FOOD AND RURAL AFFAIRS, THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: John McGiven, David Bundle, Laurence Howells, Julie Guiard, Vijaya Ganesh Narayanaswamy
  • Patent number: 10201634
    Abstract: The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: February 12, 2019
    Assignees: Brown University, National Research Council of Canada, The Governors of the University of Alberta
    Inventors: Thomas J. Webster, Hicham Fenniri, Usha Devi Hemraz